US and Neurodevelopmental Outcomes in the Neonatal Intensive Care Unit (NICU)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05071508 |
Recruitment Status :
Recruiting
First Posted : October 8, 2021
Last Update Posted : December 1, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Premature Birth |
The specific aims are as follows:
- To identify clinical factors that are associated with muscle and adipose tissue measurements. The investigators will examine the relationship between clinical factors such as calorie and protein intake during hospitalization, days on parenteral nutrition, C-Reactive Protein and other clinical surrogates for inflammation and both muscle and adipose tissue measured bi-weekly using bedside ultrasound. The investigators will collect anthropometric and ultrasound measurements bi-weekly and whole body composition (utilizing ADP) data at 35 weeks postmenstrual age (PMA)/discharge from the Neonatal Intensive Care Unit. All other clinical data will be collected throughout the hospital stay.
- To determine whether muscle thickness and cross-sectional area are predictive of improved neurodevelopmental outcomes. The investigators will assess the relationship between ultrasound measurements of muscle with neurodevelopmental outcomes at 35 weeks PMA/discharge and 4 months corrected age. The investigators will utilize Event Related Potentials (ERP) to measure speed of processing and recognition memory as early markers of brain development.
- To determine whether measurements of adipose tissue are predictive of later adverse metabolic outcomes. The investigators will assess the relationship between adipose tissue thickness and blood pressure and total body adiposity (using air-displacement plethysmography) at 35 weeks PMA/discharge and 4 months corrected age.
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Ability of Bedside Ultrasound to Predict and Optimize Metabolic and Neurodevelopmental Outcomes in Premature Infants in the Neonatal Intensive Care Unit |
Actual Study Start Date : | February 20, 2020 |
Estimated Primary Completion Date : | January 2025 |
Estimated Study Completion Date : | August 2027 |
Group/Cohort |
---|
Preterm Infants
Premature infants (born between 25 and 34 + 6 weeks gestational age) admitted to the University of Minnesota Masonic Children's Hospital NICU
|
- Blood pressure at 35 weeks [ Time Frame: 35 weeks corrected age ]blood pressure (systolic and diastolic)
- Blood pressure at 4 mo [ Time Frame: 4 months corrected age ]blood pressure (systolic and diastolic)
- Weight data inpatient [ Time Frame: 35 weeks corrected age ]weight in kg
- Length data inpatient [ Time Frame: 35 weeks corrected age ]length in cm
- Weight data outpatient [ Time Frame: 4 months corrected age ]weight in kg
- Length data outpatient [ Time Frame: 4 months corrected age ]length in cm
- Fat mass inpatient [ Time Frame: 35 weeks corrected age ]fat mass (kg)
- Fat-free mass inpatient [ Time Frame: 35 weeks corrected age ]fat-free mass (kg)
- Percent body fat inpatient [ Time Frame: 4 months corrected age ]percent body fat (kg/kg)
- Fat mass outpatient [ Time Frame: 4 months corrected age ]fat mass (kg)
- Fat-free mass outpatient [ Time Frame: 4 months corrected age ]fat-free mass (kg)
- Percent body fat outpatient [ Time Frame: 4 months corrected age ]percent body fat (kg/kg)
- Ultrasound adipose measures inpatient [ Time Frame: 35 weeks corrected age ]adipose tissue (cm)
- Ultrasound muscle measures inpatient [ Time Frame: 35 weeks corrected age ]muscle thickness (cm)
- Ultrasound adipose measures outpatient [ Time Frame: 4 months corrected age ]adipose tissue (cm)
- Ultrasound muscle measures outpatient [ Time Frame: 4 months corrected age ]muscle measurements (cm)
- ERP data inpatient [ Time Frame: 35 weeks corrected age ]ERP paradigm
- ERP data outpatient [ Time Frame: 4 months corrected age ]ERP paradigms

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Weeks to 34 Weeks (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- preterm infants born between 25 and 34+6 weeks gestation admitted to University of Minnesota Masonic Children's Hospital Neonatal Intensive Care Unit
- medically stable at time of air displacement measurements
Exclusion Criteria:
- infants that require medical support preventing ADP measurements from being taken

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05071508
Contact: Emily M Nagel, PhD | 6122737698 | nagel127@umn.edu |
United States, Minnesota | |
University of Minnesota | Recruiting |
Minneapolis, Minnesota, United States, 55454 | |
Contact: Emily Nagel, PhD |
Principal Investigator: | Sara E Ramel, MD | University of Minnesota |
Responsible Party: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT05071508 |
Other Study ID Numbers: |
PEDS-2020-28483 |
First Posted: | October 8, 2021 Key Record Dates |
Last Update Posted: | December 1, 2021 |
Last Verified: | November 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications |